TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03341832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: oral dose for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203-R
Description: oral dose for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203 placebo
Description: oral dose for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVP-1203 placebo
Description: oral dose for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R placebo
Description: oral dose for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVP-1203-R placebo
Description: oral dose for 7 days
Study: NCT02071355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 100 mg
Description: Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg
Description: Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
Study: NCT02635828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg IV
Description: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV
Description: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg IV
Description: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
Study: NCT03767920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: TAP block with 20 ml of 0.25% bupivacaine bilaterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: TAP block with 20 ml of 0.25% bupivacaine bilaterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: TAP block with 4 mg dexamethasone bilaterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to dexamethasone
Description: TAP block with 4 mg placebo to dexamethasone bilaterally
Study: NCT00854035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0431/ONO-5435
Description: Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
Study: NCT04991181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg BIA 5-1058
Description: Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
Study: NCT00854035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-0431/ONO-5435
Description: Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study: NCT01483911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Description: Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
Study: NCT02434731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Description: Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
Study: NCT00312494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with mood stabilizer (either lithium or divalproex)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
Study: NCT01002755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01066624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse
Description: Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
Study: NCT00412360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Umbilical Cord Blood Unit Transplant
Description: Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Umbilical Cord Blood Unit Transplant
Description: Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
Study: NCT01002755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study: NCT02771990

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: sham stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 2 milliamp (mA) 20 minutes
Study: NCT00925418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frozen Glove
Description: Using frozen glove during chemotherapy with Taxotere®
Study: NCT02674867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study: NCT02691299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Study: NCT03995706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
Study: NCT03240159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix
Study: NCT03094065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT04772508

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling and root planing
Description: 15 sites with periodontal pockets ≥ 5mm received only SRP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: 15 sites with periodontal pockets ≥ 5mm received only SRP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: 15 sites with periodontal pockets ≥ 5mm received only SRP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amnion membrane
Description: 15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amnion membrane
Description: 15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: 15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
Study: NCT04541628

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIG-001
Description: Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
Study: NCT00391612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhale® Drug-Eluting Stent
Description: Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: 5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
Study: NCT03320590

Intervention type: DIAGNOSTIC_TEST
Intervention: Time Lapse (material to observe embryonic development)
Description: The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
Study: NCT00156390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echo-guided left ventricular lead placement
Description: placement of the LV lead of the biventricular pacing device under echocardiographic guidance

Intervention type: OTHER
Group type: OTHER
Intervention: LV lead placement as per standard of care (without echo guidance)
Study: NCT02085278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Micro Catheter device
Description: Detachable Tip Micro catheter
Study: NCT01847976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
Study: NCT00412360

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
Study: NCT00950742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Load: 4mg/kg-maintain:2mg/kg/week
Study: NCT00412360

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
Study: NCT03529201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCA
Description: Patient-controlled analgesia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCA
Description: Patient-controlled analgesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA
Description: General anesthesia
Study: NCT00950742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Increased dose cohorts from low dose to MTD
Study: NCT02691299

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Study: NCT03529201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA
Description: General anesthesia
Study: NCT02652078

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
Study: NCT00702403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04272528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uniform care
Description: The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
Study: NCT02101489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: 20 with intraoperative Foley catheter measurement of the urethral length and 20 without
Study: NCT04272528

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional care
Description: Nurses carry out the routine care procedures.
Study: NCT01204476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study: NCT01742013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCJBP Laennec Inj.
Description: Test drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study: NCT01204476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04749953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus floor augmentation
Description: The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor augmentation
Description: The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor augmentation
Description: The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
Study: NCT01508975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Rice, Brown Rice, Glucose
Description: white rice, brown rice, glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Rice, Brown Rice, Glucose
Description: white rice, brown rice, glucose
Study: NCT02195141

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fraction
Description: capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB
Description: Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
Study: NCT00773747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bortezomib
Description: 1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to vorinostat
Description: Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
Study: NCT03270891

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PGx test
Description: A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PGx test
Description: A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
Study: NCT02540668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally
Study: NCT04360876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo delivered intravenously on the same dosing schedule as dexamethasone
Study: NCT00098306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy
Description: Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
Study: NCT02971150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Study: NCT04922905

Intervention type: OTHER
Group type: OTHER
Intervention: NEURO +
Description: The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed.

Intervention type: OTHER
Group type: OTHER
Intervention: NEURO -
Description: The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)